Ibrutinib Therapy and <i>Mycobacterium chelonae</i> Skin and Soft Tissue Infection.

Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection.

Dousa, Khalid M; Babiker, Ahmed; Van Aartsen, Daniel; Shah, Neel; Bonomo, Robert A; Johnson, John L; Skalweit, Marion J.

Afiliação

Dousa KM; Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Babiker A; Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Ohio.
Van Aartsen D; Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Shah N; Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Ohio.
Bonomo RA; Infectious Diseases Section, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio.
Johnson JL; Departments of Medicine, Pharmacology, Molecular Biology and Microbiology, Biochemistry, Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Skalweit MJ; CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio.

Open Forum Infect Dis ; 5(7): ofy168, 2018 Jul.

Article em En | MEDLINE | ID: mdl-30090839

ABSTRACT

Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first case of Mycobacterium chelonae skin and soft tissue infection in a patient receiving ibrutinib and recount the challenges in treating this infection.

Palavras-chave

Mycobacterium chelonae; chronic lymphocytic leukemia; ibrutinib; nontuberculous mycobacteria; skin and soft tissue infection

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article